Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success
Jazz Pharmaceuticals’ XYWAV™ (calcium, magnesium, potassium, and sodium oxybates) is the first US Food and Drug Administration (FDA) approved medicine indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy in over 15 years.
Our analysts are closely monitoring the impact of Covid-19 on the oncology landscape, and the following infographics break down the oncology clinical trials, which have been terminated or suspended due to Covid-19.
Earlier this month, Phase IIb results were published for Shield Therapeutics’ PT20 (ferric iron oxide adipate), an oral iron-based phosphate binder, for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney disease (CKD) patients.
Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that results in mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping.